That's not improper criticism. Remember caspase inhibitor development history, GS9450 was doing very good on those 2-4 weeks liver marker studies in HCV and NASH, but discontinued due to safety issue from larger and longer term (6-month) study in HCV.
Market Data 
Markets 
AI
